text.skipToContent text.skipToNavigation
Need help? Please contact us

Challenges of NK cells in immunotherapy

While the potential of NK cells to be effective in immunotherapy is huge, there are clear challenges to overcome before we can fully realize that potential. 

 
Three such challenges are the ability to control survival and proliferation after transplantation, migration to tumor sites, and targeting and destruction of specific cells.   
 
Carlsten and Childs recently published a review article in Frontiers in Immunology that nicely summarizes gene modification strategies to improve the ability of NK cells to persist and expand in vivo, migrate to tumor sites, and enhance cancer cell cytotoxicity (see figure below).  

The combination of advances in our understanding of the basic biology of NK cells, and enhanced technology for use in genetic manipulation are lighting the way to a promising arena for fighting cancer. But there is a lot of research still to be done before we can fully realize the potential of NK cells in immunotherapy. 

Lonza is committed to supporting your NK cell research, which is why we offer research use NK cells as well as Nucleofector™ Technology. Please contact Scientific Support for more information.
Empowering NK cell immuno-therapy research using a novel genome editing protocol
Article
CRISPR/Cas9-based gene engineering of human NKs:
Protocols for Knockout and Readouts to Evaluate Their Efficacy
Summary of strengths:
CAR-NK cells and automated production for immunotherapy
Article

References

Carlsten M, Childs RW. Genetic manipulation of NK cells for cancer immunotherapy: Techniques and clinical implications. Front Immunol. 2015 Jun 10:6:266

Cho, D, Kim SK, Carson WE. NK cell-based immunotherapy for treating cancer: will it be promising? Korean J Hematol. 2011 Mar; 46(1):3-5

Kumar V, McNerney ME. A new self: MHC-class-I-independent natural-killer-cell self-tolerance. Nat Rev immunol. 2005 May; 5(5):363-74

Lim O, Jung MY, Hwang YK, Shin EC. Present and future of allogeneic natural killer cell therapy. Front Immunol. 2015; 6:286